Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms

Clinical Therapeutics

Volumn 38, Issue 3, 2016, Pages 431-444

  Sharma, Roopali ^a   Eun Park, Tae ^b   Moy, Stanley ^c  

^a LONG ISLAND UNIVERSITY   (United States)

^b FAIRLEIGH DICKINSON UNIVERSITY   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

avibactam; carbapenemase producing organisms; ceftazidime avibactam; cephalosporin lactamase inhibitor; MDR gram negative organisms

Indexed keywords

AVIBACTAM; AVIBACTAM PLUS CEFTAZIDIME; BACTERIAL ENZYME; BETA LACTAMASE AMPC; CARRIER PROTEIN; CEFTAZIDIME; CHLORAMPHENICOL; CYTOCHROME P450; EXTENDED SPECTRUM BETA LACTAMASE; ORAL CONTRACEPTIVE AGENT; PROBENECID; AMPC BETA-LACTAMASES; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEMASE; CEPHALOSPORIN DERIVATIVE;

ABDOMINAL INFECTION; ANAPHYLAXIS; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; DIARRHEA; DRUG SAFETY; FEVER; GASTROINTESTINAL DISEASE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; NAUSEA; NEUROLOGIC DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SKIN MANIFESTATION; SYSTEMATIC REVIEW; URINARY TRACT INFECTION; VOMITING; BIOSYNTHESIS; DRUG EFFECTS; ENZYMOLOGY; GRAM-NEGATIVE BACTERIAL INFECTIONS; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CEFTAZIDIME; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS;

EID: 84961169202     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.01.018     Document Type: Review

References (41)

1. Centers for Disease Control and Prevention (CDC). Antibiotic resistance treats in the United States, 2013. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed September 6, 2015.
2. K. Bush Bench-to-bedside review: the role of beta-lactamases in antibiotic-resistant Gram-negative infections Crit Care 14 2010 224
3. K. Bush, and G.A. Jacoby Updated functional classification of β-lactamases Antimicrob Agents Chemother 54 2010 969 976
4. D.L. Paterson, and R.A. Bonomo Extended-spectrum β-lactamases: a clinical update Clin Microbiol Rev 18 2005 657 686
5. Fortaz® (ceftazidime) [package insert] Research Triangle Park 2007 GlaxoSmithKline NC
6. K. Bush Alarming beta-lactamase-mediated resistance in multi-drug-resistant Enterobacteriaceae Curr Opin Microbiol 13 2010 558 564
7. J.D. Pitout Infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices Drugs 70 2010 313 333
8. D.M. Livermore, and N. Woodford The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter Trends Microbiol 14 2006 413 420
9. Center for Drug Evaluation and Research, US Food and Drug Administration. Avycaz (ceftazidime-avibactam) FDA summary review. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM425458.pdf. Accessed October 5, 2015.
10. A. Endimiani, Y. Choudhary, and R.A. Bonomo In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases Antimicrob Agents Chemother 53 2009 3599 3601
11. Avycaz® (ceftazidime/avibactam) [package insert] Cincinnati 2015 Forest Pharmaceuticals, Inc. OH
12. P. Lagacé-Wiens, A. Walkty, and J.A. Karlowsky Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections Core Evid 9 2014 13 25
13. E.J. Zasowski, J.M. Rybak, and M.J. Rybak The β-lactams strike back: ceftazidime-avibactam Pharmacotherapy 35 2015 755 770
14. M.G. Pinho, M. Kjos, and J.W. Veening How to get (a)round: mechanisms controlling growth and division of coccoid bacteria Nat Rev Microbiol 11 2013 601 614
15. E. Sauvage, F. Kerff, M. Terrak, and et al. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis FEMS Microbiol Rev 32 2008 234 258
16. P. Macheboeuf, C. Contreras-Martel, V. Job, and et al. Penicillin binding proteins: key players in bacterial cell cycle and drug resistance processes FEMS Microbiol Rev 30 2006 673 691
17. S.M. Drawz, and R.A. Bonomo Three decades of beta-lactamase inhibitors Clin Microbiol Rev 23 2010 160 201
18. S.D. Lahiri, S. Mangani, T. Durand-Reville, and et al. Structural insight into portent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC beta-lactamases Antimicrob Agents Chemother 57 2013 2496 2505
19. M. Castanheira, J.C. Mills, S.E. Costello, and et al. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains Antimicrob Agents Chemother 59 2015 3509 3517
20. R.K. Flamm, H.S. Sader, D.J. Farrell, and et al. Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011) Diagn Microbiol Infect Dis 80 2014 233 238
21. P. Levasseur, A.M. Girard, M. Claudon, and et al. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates Antimicrob Agents Chemother 56 2012 1606 1608
22. C. Pitart, F. Marco, T.A. Keating, and et al. Activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa Antimicrob Agents Chemother 59 2015 3059 3065
23. H.S. Sader, M. Castanheira, R.K. Flamm, and et al. Ceftazidime/avibactam tested against gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia Int J Antimicrob Agents 46 2015 53 59
24. H.S. Sader, M. Castanheira, R.E. Mendes, and et al. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013 Antimicrob Agents Chemother 59 2015 3656 3659
25. R.K. Shields, C.J. Clancy, B. Hao, and et al. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae Antimicrob Agents Chemother 59 2015 5793 5797
26. R. Testa, R. Canton, T. Giani, and et al. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European gram-negative and gram-positive clinical isolates Int J Antimicrob Agents 45 2015 641 646
27. D.M. Citron, K.L. Tyrrell, V. Merriam, and et al. In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes Antimicrob Agents Chemother 55 2011 3616 3620
28. Sader HS, Castanheira M, Flamm RK, et al. Ceftazidime-avibactam activity tested against aerobic gram-negative organisms isolated from intraabdominal infections in United States hospitals (2012-2014). Abstract presented at: Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC); September 17-21, 2015; San Diego, CA. Abstract C-140.
29. H. Merdjan, M. Rangaraju, and A. Tarral Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies Clin Drug Investig 35 2015 307 317
30. N. Tominaga, T. Edeki, J. Li, and et al. Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers J Infect Chemother 21 2015 551 558
31. K. Vishwanathan, S. Mair, A. Gupta, and et al. Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potential Drug Metab Dispos 42 2014 932 942
32. J. Dallow, L.G. Otterson, M.D. Huband, and et al. Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes Int J Antimicrob Agents 44 2014 552 556
33. C. Lucasti, I. Popescu, M.K. Ramesh, and et al. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial J Antimicrob Chemother 68 2013 1183 1192
34. J.A. Vazquez, L.D. González Patzán, D. Stricklin, and et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study Curr Med Res Opin 28 2012 1921 1931
35. Mazuski JE, Gasnik L, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection - results from a Phase III program. Abstract presented at: 25th European Congress of Clinical Microbiology and Infectious Diseases; April 25-28, 2015; Copenhagen, Denmark. Abstract O191.
36. Carmeli Y, Armstrong J, Laud PJ, et al. Efficacy and safety of ceftazidime-avibactam and best available therapy in the treatment of ceftazidime-resistant infections - results from a Phase III study. Abstract presented at: 25th European Congress of Clinical Microbiology and Infectious Diseases; April 25-28, 2015; Copenhagen, Denmark. Abstract LBEV0061b.
37. ClinicalTrials.gov. Ceftazidime-avibactam compared with doripenem followed by oral therapy for hospitalized adults with complicated UTIs. https://clinicaltrials.gov/ct2/show/NCT01599806. Accessed August 26, 2015.
38. ClinicalTrials.gov. Ceftazidime-avibactam compared with doripenem followed by oral therapy for hospitalized adults with complicated UTIs. https://clinicaltrials.gov/ct2/show/NCT01595438. Accessed August 26, 2015.
39. ClinicalTrials.gov. A study comparing ceftazidime-avibactam versus meropenem in hospitalized adults with nosocomial pneumonia. https://clinicaltrials.gov/ct2/show/NCT01808092. Accessed August 26, 2015.
40. Gallagher JC., Cprek J, Famon E, et al. Compassionate use ceftazidime/avibactam (CAZ-AVI) for carbapenem-resistant Klebsiella pneumoniae (CRKP) infections. Abstract presented at: 18th Making a Difference in Infectious Diseases (MAD-ID) Meeting; May 7-9, 2015; Orlando, FL.
41. S. Das, J. Armstrong, D. Mathews, and et al. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam J Clin Pharmacol 54 2014 331 340